Loading...

NKTR NEKTAR THERAPEUTICS Expansion Plans 8-K Filing

NKTR

NKTR

NEKTAR THERAPEUTICS

(NKTR)

2025 8-K

Equity Agreement Filed

Financial Results Announced

Stock Offering Announcement

Cash Position Update

Study Results Released

Financial Results

Stock Offering Announcement

Cash Position Update

Study Results Released

Quiet Period Announcement

Clinical Trial Results

Management Change

New Clinical Data

Financial Results

New Clinical Data

Financial Statements

Equity Offerings

Compliance Issues

Product Expansion

Reverse Stock Split

Reverse Stock Split

Financial Statements

Financial Results

Clinical Trial Agreement

Management Change

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results

Compliance with Minimum Bid...

Amendment to Purchase Agree...

Securities Purchase Agreement

Stock Repurchase

Earnings Reports

Financial Results Announcement

Financial Results Announcement

Disclosure and Other Events

Management Change

Annual Meeting of Stockholders

Financial Results Announcement

Termination of Agreement

Restructuring Plan and CFO ...

External Links:

On December 16, 2025, Nektar Therapeutics announced the topline results from its Phase 2b REZOLVE-AA clinical trial for alopecia areata, showing a mean SALT score reduction of 28.2% for the 24 µg/kg dosage and 30.3% for the 18 µg/kg dosage compared to 11.2% for placebo, with some results reaching statistical significance after excluding specific eligibility violations.

AI Assistant

NEKTAR THERAPEUTICS

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.